Your browser doesn't support javascript.
Complement as a target in COVID-19?
Risitano, Antonio M; Mastellos, Dimitrios C; Huber-Lang, Markus; Yancopoulou, Despina; Garlanda, Cecilia; Ciceri, Fabio; Lambris, John D.
  • Risitano AM; Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  • Mastellos DC; National Center for Scientific Research 'Demokritos', Aghia Paraskevi, Athens, Greece.
  • Huber-Lang M; Institute of Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany.
  • Yancopoulou D; Amyndas Pharmaceuticals, Glyfada, Greece.
  • Garlanda C; Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
  • Ciceri F; Humanitas University, Pieve Emanuele, Milan, Italy.
  • Lambris JD; IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy. ciceri.fabio@hsr.it.
Nat Rev Immunol ; 20(6): 343-344, 2020 06.
Article in English | MEDLINE | ID: covidwho-116407
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Complement System Proteins / Coronavirus Infections / Complement Activation Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: S41577-020-0320-7

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Complement System Proteins / Coronavirus Infections / Complement Activation Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: S41577-020-0320-7